Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lane, Denis ^a   Matte, Isabelle ^a   Rancourt, Claudine ^a   Piché, Alain ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8;

ARTICLE; ASCITES TUMOR; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIAL OVARIAN CANCER; FEMALE; HUMAN; HUMAN TISSUE; OVARY CANCER; PREDICTION; PROGNOSIS; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; ASCITES; METABOLISM; MORTALITY; NEOPLASM; OVARY TUMOR; PATHOPHYSIOLOGY; SURVIVAL;

ASCITES; FEMALE; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 79957466111     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-210     Document Type: Article

References (42)

1. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999, 49:297-320. 10.3322/canjclin.49.5.297, 11198956.
2. Shen-Gunther J, Mannel RS. Ascites as a predictor of ovarian malignancy. Gynecol Oncol 2002, 87:77-83. 10.1006/gyno.2002.6800, 12468346.
3. Lane D, Robert V, Grondin R, Rancourt C, Piché A. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt in human ovarian carcinoma cells. Int J Cancer 2007, 121:1227-1237. 10.1002/ijc.22840, 17534891.
4. Lane D, Goncharenko-Khaider N, Rancourt C, Piché A. Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010, 29:3519-3531. 10.1038/onc.2010.107, 20400979.
5. Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM. Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007, 9:820-829. 10.1593/neo.07472, 2040209, 17971902.
6. Lane D, Matte I, Rancourt C, Piché A. The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer. J Ovarian Res 2010, 3:1. 10.1186/1757-2215-3-1, 2821314, 20157422.
7. Mills GB, May C, McGill M, Roifman CM, Mellors A. A putative new growth factor in ascitic fluid from ovarian cancer patients: identification, characterization, and mechanism of action. Cancer Res 1988, 48:1066-1071.
8. Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A. Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990, 86:851-855. 10.1172/JCI114784, 296802, 2394835.
9. Richardson M, Gunawan J, Hatton MW, Seidlitz E, Hirte HW, Singh G. Malignant ascites fluid (MAF), including ovarian cancer-associated MAF, contains angiostatin and other factor(s) which inhibit angiogenesis. Gynecol Oncol 2002, 86:279-287. 10.1006/gyno.2002.6760, 12217749.
10. Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A, Holub BJ, Mills GB. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995, 1:1223-1232.
11. Yamada T, Sato K, Komachi M, Malchinkhuu E, Tobo M, Kimura T, Kuwabara A, Yanagita Y, Ikeya T, Tanahashi Y, Ogawa T, Ohwada S, Morishita Y, Ohta H, Im DS, Tamoto K, Tomura H, Okajima F. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. J Biol Chem 2004, 279:6595-6605.
12. Giuntoli RL, Webb TJ, Zoso A, Rogers O, Diaz-Montes TP, Bristow RE, Oelke M. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009, 29:2875-2884.
13. Radke J, Schmidt D, Böhme M, Schmidt U, Weise W, Morenz J. Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd 1996, 56:83-87. 10.1055/s-2007-1022247, 8647364.
14. Ahmed N, Riley C, Oliva K, Rice G, Quinn M. Ascites induces modulation of α6β1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma. Br J Cancer 2005, 92:1475-1485. 10.1038/sj.bjc.6602495, 2362012, 15798771.
15. Offner FA, Obrist P, Stadlmann S, Feichtinger H, Klinger P, Herold M, Zwierzina H, Hittmair A, Mikuz G, Abendstein B, Zeimet A, Marth C. Il-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995, 7:542-547. 10.1006/cyto.1995.0073, 8580370.
16. Asschert JG, Vellenga E, Ruiters MH, de Vries EG. Regulation of spontaneous and TNF/IFN-induced IL-6 expression in two human ovarian-carcinoma cell lines. Int J Cancer 1999, 82:244-249. 10.1002/(SICI)1097-0215(19990719)82:2<244::AID-IJC15>3.0.CO;2-N, 10389759.
17. Asschert JG, de Vries EG, De Jong S, Withoff S, Vellenga E. Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1. Int J Cancer 1999, 81:236-242. 10.1002/(SICI)1097-0215(19990412)81:2<236::AID-IJC12>3.0.CO;2-R, 10188725.
18. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990, 50:6959-6965.
19. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Stimulation of ovarian tumor cell proliferation with monocyte products inducing interleukin 1, interleukin 6 and tumor necrosis factor-alpha. Am J Obstet Gynecol 1992, 166:977-1007.
20. Hsu SM, Hsu PL. Autocrine and paracrine functions of cytokines in malignant lymphomas. Biomed Pharmacother 1994, 48:433-444. 10.1016/0753-3322(94)90004-3, 7858153.
21. Nakazaki H. Preoperative and postoperative cytokines in patients with cancer. Cancer 1992, 70:709-713. 10.1002/1097-0142(19920801)70:3<709::AID-CNCR2820700328>3.0.CO;2-O, 1320454.
22. Syed V, Ulinski G, Mok SC, Ho SM. Reproductive hormone-induced, STAT3-mediated interleukin 6 action in normal and malignant human ovarian surface epithelial cells. J Natl Cancer Inst 2002, 94:617-629.
23. Obata NH, Tamakoshi K, Shibata K, Kikkawa F, Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res 1997, 17:337-342.
24. Nilsson MB, Langley RR, Fidler IJ. Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine. Cancer Res 2005, 65:10794-10800. 10.1158/0008-5472.CAN-05-0623, 1534114, 16322225.
25. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010, 285:35462-35470. 10.1074/jbc.M110.109579, 20826776.
26. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997, 66:27-30. 10.1006/gyno.1997.4726, 9234916.
27. Scambia G, Testa U, Panici PB, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C, Mancuso S. Prognostic significance of interleukin 6 serum levels in patients with ovarian cancer. Br J Cancer 1995, 71:354-356. 10.1038/bjc.1995.71, 2033591, 7841052.
28. Plante M, Rubin SC, Wong GY, Federici MG, Finstad CL, Gastl GA. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer. Cancer 1994, 73:1882-1888. 10.1002/1097-0142(19940401)73:7<1882::AID-CNCR2820730718>3.0.CO;2-R, 8137215.
29. Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart MJ, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E. Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide. J Clin Oncol 2006, 24:45-51. 10.1200/JCO.2005.01.2757, 16382112.
30. Garg R, Wollan M, Galic V, Garcia R, Goff BA, Gray HJ, Swisher E. Common polymorphism in interleukin 6 influences survival of women with ovarian and peritoneal carcinoma. Gynecol Oncol 2006, 103:793-796. 10.1016/j.ygyno.2006.08.043, 2562602, 17023036.
31. Johnson MT, Gotlieb WH, Rabbi M, Martinez-Maza O, Berek JS. Induction of cisplatin resistance and metallothionein expression by interleukin-6. Gynecol Oncol 1993, 49:110.
32. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Valdya A, Hampel C, Lee H, Seiden MV. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res 2006, 12:5055-5063. 10.1158/1078-0432.CCR-06-0861, 16951221.
33. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL)-6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistance phenotype. Clin Cancer Res 1999, 5:3445-3453.
34. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 1998, 153:1249-1256. 10.1016/S0002-9440(10)65669-6, 1853065, 9777956.
35. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, Chang JS, Lai TC, Rose-John S, Kuo ML, Wei LH. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res 2011, 71:424-434. 10.1158/0008-5472.CAN-10-1496, 21123455.
36. Guo Y, Nemeth J, O'Brien C, Susa M, Liu X, Zhang Z, Choy E, Mankin H, Hornicek F, Duan Z. Effects of siltuximab on the IL-6-induced signaling pathway in ovarian cancer. Clin Cancer Res 2010, 16:5759-5769. 10.1158/1078-0432.CCR-10-1095, 20699329.
37. Van Rhee F, Fayad L, Voorhees P, Furman R, Lional S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castelman's disease. J Clin Oncol 2010, 28:3701-3708. 10.1200/JCO.2009.27.2377, 20625121.
38. Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, Navarro R, Lopez E, Quittet P, Daures JP, Rouille V, Kanouni T, Widjenes J, Klein B. Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects. Bone Marrow Transplantation 2005, 36:771-779. 10.1038/sj.bmt.1705138, 2034604, 16113665.
39. Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006, 203:871-881. 10.1084/jem.20050930, 2118300, 16606666.
40. Punnonen R, Teisala K, Kuoppala T, Bennett B, Punnonen J. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer 1998, 83:788-796. 10.1002/(SICI)1097-0142(19980815)83:4<788::AID-CNCR24>3.0.CO;2-N, 9708947.
41. Yigit R, Figdor CG, Zusterzeel PM, Pots JM, Torensma T, Massuger LG. Cytokine analysis as a tool to understand tumour-host interaction in ovarian cancer. Eur J Cancer 2011,
42. Schauer IG, Sood AK, Mok S, Liu J. Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer. Neoplasia 2011, 13:393-405. 3084616, 21532880.